C-4-29 / Chongqing Precision Biotech - LARVOL DELTA

Safety and Efficacy of B Cell Maturation Antigen (BCMA)/CD70-Targeted Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Pediatric Patients with Multidrug-Resistant, Steroid-Resistant Nephrotic Syndrome (KIDNEY WEEK 2025) - P1 | "Methods In this Phase I/II study (NCT06553898), C-4-29 CAR T cells were manufactured by the PRIMCAR manufacturing platform. However, as of the latest assessment, 5 exhibited an increase in urinary protein excretion, suggesting disease relapse. Conclusion BCMA/CD70-targeted CAR T-Cell therapy demonstrates favorable safety profile in pediatric patients with MDR-SRNS while shedding light on disease pathogenesis.The expected completion time of this research is July 2027."

CAR T-Cell Therapy • Clinical • Late-breaking abstract • Glomerulonephritis • Nephrology • Pediatrics • Renal Disease • CD70

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=18 | Enrolling by invitation | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial primary completion date: Sep 2022 ➔ Dec 2023

CAR T-Cell Therapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology